Location: Sydney, Australia


Event description:

Visit the Novotech table top exhibit #10 at ASCEPT 2023 in Sydney from November 20 – 23 to discover solutions to accelerate your clinical development. ASCEPT is the pinnacle event in clinical and experimental pharmacology and toxicology in Australia.

With extensive experience and a strong track record, Novotech has established itself as a key player in providing CRO services to biotechnology companies in Australia and other key markets. Our commitment to delivering high-quality and innovative solutions has positioned us as a trusted partner in advancing clinical and experimental research.

At DDC, an integral part of Novotech, we provide dedicated and strategic product development, collaborating with clients for successful biotech, drug, and device approvals from global regulators.

Our experts will be on-site, ready to discuss how our extensive experience can benefit your research projects. Connect with us at ASCEPT 2023 and discover the impact Novotech is making in advancing clinical research in Asia Pacific, Europe and the US.

Presentation details:

You won’t want to miss the poster presentations:

  • Nonclinical and Manufacturing Considerations for Novel Live Biotherapeutic Products
  • Dr. Sharleen Menezes
  • Tues Nov. 21 9:30 - 10:25 


  • What is a Non-Significant Risk Device Clinical Study?
  • Melissa Dworak
  • Tues Nov. 21 12:30 - 1:25 pm


  • Nonclinical and CMC Considerations for the Development of siRNA Therapeutics
  • Sweta Kumar
  • Poster on display from Tues Nov. 21 9:30- 10:25 am

Schedule a meeting with our attendees

Meet Our Team

Drug Development Consulting

Felicity Grzemski

Drug Development Consulting
Principal Toxicologist

Nicholas (Nick) Rich

Regional Director Business Development
Novotech DDC

Melissa Dworak

Novotech DDC
Novotech DDC

Sweta Kumar

Novotech DDC

Plus experts from our China, Drug Development, and global Commercial teams.